The efficacy of shortening the dosing interval to once every six weeks in Crohn's patients losing response to maintenance dose of infliximab.
about
Therapeutic drug monitoring in inflammatory bowel diseaseBiologics in the management of ulcerative colitis - comparative safety and efficacy of TNF-α antagonistsInfliximab dosing patterns in a sample of patients with Crohn's disease: results from a medical chart reviewSignificance of low level infliximab in the absence of anti-infliximab antibodies.Outcomes after escalation of infliximab therapy in ambulatory patients with moderately active ulcerative colitisSpecialized enteral nutrition therapy in Crohn's disease patients on maintenance infliximab therapy: a meta-analysis.Efficacy and Safety of Escalation of Adalimumab Therapy to Weekly Dosing in Pediatric Patients with Crohn's Disease.Review article: Causative factors and the clinical management of patients with Crohn's disease who lose response to anti-TNF-α therapy.Anti-TNF trough levels and detection of antibodies to anti-TNF in inflammatory bowel disease: are they ready for everyday clinical use?Review article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease.Tailoring anti-TNF therapy in IBD: drug levels and disease activity.Management of inflammatory bowel disease in poor responders to infliximab.Progress with anti-tumor necrosis factor therapeutics for the treatment of inflammatory bowel disease.Review article: The pharmacokinetics and pharmacodynamics of drugs used in inflammatory bowel disease treatment.Optimizing biological therapy in Crohn's disease.Anti-TNF drug and antidrug antibody level monitoring in IBD: a practical guide.Emerging therapeutic targets and strategies in Crohn's disease.Therapeutic Drug Monitoring and Clinical Outcomes in Immune Mediated Diseases: The Missing Link.Current and Future Status of Therapeutic Drug Monitoring in the Treatment of IBD.Dose escalation of biologics in Crohn's disease: critical review of observational studies.Benefit of infliximab reintroduction after successive failure of infliximab and adalimumab in Crohn's disease.Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of response.Durability of infliximab dose intensification in Crohn's disease.Anti-infliximab antibody concentrations can guide treatment intensification in patients with Crohn's disease who lose clinical response.Efficacy and safety of golimumab in Crohn's disease: a French national retrospective study.Anti-TNF re-induction is as effective, simpler and cheaper compared with dose-interval shortening for secondary loss of response in Crohn's disease.Therapeutic Drug Monitoring to Guide Infliximab Dose Adjustment is Associated with Better Endoscopic Outcomes than Clinical Decision Making Alone in Active Inflammatory Bowel Disease.Approach to Optimize Anti-TNF-α Therapy in Patients With IBD.
P2860
Q26852729-CF11757B-51E2-4A26-8FE6-7E9EF3C29BD0Q26999078-77D8CBD1-FD4B-4641-995A-79724905275CQ33724975-23245E62-90C7-40B6-899A-797698DDB9D0Q35069511-E9978285-B8D9-4D8C-AB89-8AC78BD9F25DQ35752240-14E037B9-1B70-4E28-A77E-B6F0ED740C26Q35780904-903AE9C8-6C94-4EA8-92AF-4A59017B1327Q36692562-90E6F722-5283-4655-9011-09B266951AEBQ37871625-F127749B-234D-4D1A-B91B-FB549712BA5EQ37965581-E4E75891-F00F-4D93-9C7E-68A9D9262DAEQ38121115-E23BE849-444C-4780-BDD5-B767CAC78085Q38176154-81F5DDB5-9585-4706-AF82-00370DC4A6C3Q38254573-481602F4-64BA-405B-99A2-9C7C9367364EQ38365049-5BD14572-1ED2-41CA-9C21-BA702D4DEB8DQ38501680-18E14EF9-8CC8-454E-A1E0-19909FF9EF19Q38608158-97829121-0843-4A6C-B6E0-D39A13C8B084Q38608962-BE90B168-57C0-40EB-B0FB-96973BD6F381Q38696392-D2CFD820-5C93-4555-B7C3-85507C9EFD94Q38826447-7B5DDD5D-2A07-475B-A969-245F631EF750Q39278646-A2DD2E80-D808-4C67-8ADB-58EA129EF757Q39326057-EE7834E1-32CC-4DF6-9007-71B4CE59EC1CQ41640821-81A28751-D1B3-4916-A2B0-A801675B1D2CQ43576777-4709AE45-500A-4B93-AD0F-01BF60CB5733Q46354771-AF366927-7CC6-41D5-8FDC-48842C0E7C26Q48144954-2623671E-1FDB-44FC-A7A2-F074C49A957FQ48191965-917D35EE-BC7D-4BE0-B1F8-2191CF099F44Q48618165-EA344B49-F01B-4039-BACE-F61A8BB5B689Q50652815-B5A1DE13-E5EA-4D39-AB91-8DAD6DBCD8F9Q50713607-1CA60430-F44F-4C4A-8ACF-3C1099C11C14
P2860
The efficacy of shortening the dosing interval to once every six weeks in Crohn's patients losing response to maintenance dose of infliximab.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
The efficacy of shortening the ...... aintenance dose of infliximab.
@en
The efficacy of shortening the ...... aintenance dose of infliximab.
@nl
type
label
The efficacy of shortening the ...... aintenance dose of infliximab.
@en
The efficacy of shortening the ...... aintenance dose of infliximab.
@nl
prefLabel
The efficacy of shortening the ...... aintenance dose of infliximab.
@en
The efficacy of shortening the ...... aintenance dose of infliximab.
@nl
P2093
P1476
The efficacy of shortening the ...... aintenance dose of infliximab.
@en
P2093
C Reenaers
E V Tsianos
G J Mantzaris
J F Rahier
K H Katsanos
M Cesarini
P L Lakatos
P304
P356
10.1111/J.1365-2036.2010.04523.X
P407
P577
2010-12-01T00:00:00Z